Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease

被引:10
|
作者
Amacher, David E. [1 ]
机构
[1] Sciadvisor Toxicol Consulting, Hadlyme, CT 06439 USA
关键词
Non-alcoholic fatty liver disease; non-alcoholic steatosis; novel circulating biomarkers; steatohepatitis; GROWTH-FACTOR; 21; PROLIDASE ENZYME-ACTIVITY; INDUCED HEPATIC STEATOSIS; C-REACTIVE PROTEIN; SERUM FGF21 LEVELS; NONINVASIVE DIAGNOSIS; SCORING SYSTEM; CELL-DEATH; ALANINE AMINOTRANSFERASE; STEATOHEPATITIS NASH;
D O I
10.3109/1354750X.2014.958535
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Context: The definitive standard for the diagnosis of nonalcoholic fatty liver disease (NAFLD) is clinico-pathological correlation, but frequently the only laboratory abnormality is an elevation of serum aminotransferases. Objective: This has resulted in the search for more specific laboratory biomarkers. Methods: The literature was searched for novel plasma/serum markers of NAFLD. Results: Studies reviewed here included histologically-confirmed patients presenting some stage of NAFLD and monitored one or more novel serum/plasma biomarkers. Conclusion: The most promising application of some of these novel biomarkers for the detection and quantification of NAFLD and particularly NASH appears to be in the combination of several into diagnostic panels.
引用
收藏
页码:541 / 552
页数:12
相关论文
共 50 条
  • [1] Biomarkers in nonalcoholic fatty liver disease
    Neuman, Manuela G.
    Cohen, Lawrence B.
    Nanau, Radu M.
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 28 (11) : 607 - 618
  • [2] Circulating homocysteine in nonalcoholic fatty liver disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    Tsoukas, Michael A.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2015, 26 (02) : 152 - 153
  • [3] Circulating microRNAs in nonalcoholic fatty liver disease
    DiStefano, Johanna K.
    Gerhard, Glenn S.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (02) : 161 - 163
  • [4] Imaging Biomarkers for Nonalcoholic Fatty Liver Disease
    Zhang, Man
    [J]. ACADEMIC RADIOLOGY, 2019, 26 (07) : 869 - 871
  • [5] Medical progress - Nonalcoholic fatty liver disease
    Angulo, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (16): : 1221 - 1231
  • [6] Lipidomics in Nonalcoholic Fatty Liver Disease: Exploring Serum Lipids as Biomarkers for Pediatric Nonalcoholic Fatty Liver Disease
    Draijer, Laura G.
    Froon-Torenstra, Denise
    van Weeghel, Michel
    Vaz, Frederic M.
    Bohte, Anneloes E.
    Holleboom, Adriaan G.
    Benninga, Marc A.
    Koot, Bart G. P.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (04): : 433 - 439
  • [7] Circulating periostin in patients with nonalcoholic fatty liver disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    Anastasilakis, Athanasios D.
    Papatheodorou, Athanasios
    Kokkoris, Panagiotis
    Terpos, Evangelos
    [J]. ENDOCRINE, 2017, 56 (02) : 438 - 441
  • [8] Circulating miRNAs associated with nonalcoholic fatty liver disease
    Atic, Amila Iriskic
    Thiele, Maja
    Munk, Alexander
    Dalgaard, Louise Torp
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2023, 324 (02): : C588 - C602
  • [9] Circulating periostin in patients with nonalcoholic fatty liver disease
    Stergios A. Polyzos
    Jannis Kountouras
    Athanasios D. Anastasilakis
    Athanasios Papatheodorou
    Panagiotis Kokkoris
    Evangelos Terpos
    [J]. Endocrine, 2017, 56 : 438 - 441
  • [10] Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
    Gilca-Blanariu, Georgiana-Emmanuela
    Budur, Daniela Simona
    Mitrica, Dana Elena
    Gologan, Elena
    Timofte, Oana
    Balan, Gheorghe Gh
    Olteanu, Vasile Andrei
    Stefanescu, Gabriela
    [J]. METABOLITES, 2023, 13 (11)